Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025
A panelist discusses the most significant research findings on bispecific antibody therapy for relapsed/refractory multiple myeloma presented at ASCO 2025, highlighting breakthroughs and novel therapies that may shift treatment paradigms, assessing the clinical implications for improving patient management and outcomes, and exploring emerging trispecific therapies with potential to further transform future care.
Episodes
June 17th 2025EP. 1: Setting the Stage and New Milestones in Talquetamab Data
A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer durability with biweekly dosing, including in patients previously treated with B-cell maturation antigen–targeted therapies, supporting sequencing and combination strategies to improve outcomes.
June 24th 2025EP. 2: Diving Deeper: Long-Term Safety With Talquetamab
A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, emphasizing the promising efficacy and improved safety profile of GPRC5D-targeting agents, the importance of patient-specific factors in therapy selection, and the role of prophylactic measures to manage infection risks, supporting personalized treatment strategies.
July 1st 2025EP. 3: Prophylactic Tocilizumab and Sequencing Strategies in the Bispecific Era
A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient experience, while highlighting the importance of timing and sequencing T-cell–targeting therapies to optimize efficacy and immune recovery in multiple myeloma management.
July 8th 2025EP. 4: Exploring the Data From LINKER-MM
A panelist discusses early clinical trial data on combining the B-cell maturation antigen–targeting bispecific antibody linvoseltamab with proteasome inhibitors carfilzomib and bortezomib in relapsed/refractory multiple myeloma, highlighting promising response rates, manageable toxicity profiles, and the potential for these combinations to enhance treatment efficacy pending longer-term follow-up.
